Promomed company has registered a localized analogue of Trikafta, which is prescribed to patients with a rare disease — cystic fibrosis. Currently, in the segment of such drugs, the volume of which has already reached ₽22 billion in the first 9 months of 2026, there is only the original drug and its generic counterpart Trilexa, which is produced in Argentina...

Company Promomed has obtained a registration certificate in Kyrgyzstan for the drug Tirzetta, which is intended for the treatment of obesity. Prior to the registration of Tirzetta, there were no similar medications available in Kyrgyzstan.

Russian Ministry of Health has granted Promomed permission to conduct Phase I clinical trials of the first domestic bispecific oncological drug from the ADC class (antibody‑drug conjugates). Trials will be conducted with the participation of 18 medical organizations. It is planned to involve up to 60 patients with hormone‑positive, HER2‑negative recurrent or...

Promomed company has obtained a registration certificate from the Ministry of Health of Kazakhstan for the drug Tirzetta, which is used to treat type 2 diabetes and obesity. Supply of the drug to the republic will begin in the near future. Tirzetta will become the first drug based on tirzepatide on the market in Kazakhstan. Not only alternative generics, but...